ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Mustang Bio, CSL Behring Enter License Agreement for Stable Producer Cell Line
August 28, 2019Cytegrity™ is a stable producer cell line developed by St. Jude Children’s Research Hospital for the treatment of X-linked severe combined immunodeficiency. -
Aslan Pharmaceuticals amends license agreement with CSL
June 03, 2019Amending their previous agreement, CSL grants ASLAN full global rights to develop, manufacture and commercialise ASLAN004 -
CSL marks a billion dollar in profits
October 24, 2018BioSpectrum Asia Top 20 Survey Rank 2 - CSL, Australia -
CSL to purchase 80% stake in Chinese firm Ruide for $352m
June 15, 2017Global biotechnology company CSL has agreed to buy 80% stake in Chinese plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biological Products (Ruide) from Humanwell Healthcare Group for $352m. -
CSL acquires major stake in Ruide China
June 15, 2017Within the Ruide joint venture, CSL will have an opportunity to contribute capabilities across the full range of plasma products currently produced by CSL in markets outside China. -
CSL to Acquire Majority Stake in Chinese Plasma Fractionator Wuhan Zhong Yuan Rui De Biologicals Pro
June 14, 2017CSL Limited has agreed to acquire 80 per cent equity of plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biological Products Co. Ltd.
Pharma Sources Insight January 2025
